Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?

Gynecologic Oncology

Volumn 120, Issue 2, 2011, Pages 229-232

  Vineyard, Marisa A ^a,e   Daniels, Molly S ^b   Urbauer, Diana L ^c   Deavers, Michael T ^c   Sun, Charlotte C ^b   Boerwinkle, Eric ^d   Bodurka, Diane C ^b   Gershenson, David M ^b   Crawford, Jessica ^b   Lu, Karen H ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Hereditary breast and ovarian cancer; Low grade histopathology; Ovarian cancer; Risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEREDITARY BREAST AND OVARIAN CANCER; HIGH GRADE SEROUS OVARIAN CANCER; HISTOPATHOLOGY; HUMAN; LOW GRADE SEROUS OVARIAN CANCER; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICAL RECORD REVIEW; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPECTRUM; TUMOR;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79251598279     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.033     Document Type: Article

References (21)

1. A. Horiuchi, K. Itoh, M. Shimizu, I. Nakai, T. Yamazaki, and K. Kimura Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach Gynecol Oncol 88 2003 309 317
2. I. Shih, and R.J. Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 5 2004 May 1511 1518
3. C.N. Landen, M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol 26 6 2008 Feb 20 1 11
4. M.G. Teneriello, M. Ebina, R.I. Linnoila, M. Henry, J.D. Nash, and R.C. Park p53 and Ki-rase gene mutations in epithelial ovarian neoplasms Cancer Res 53 1993 Jul 1 3103 3108
5. G. Singer, R.J. Kurman, H. Chang, S.K.R. Cho, and I. Shih Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 4 2002 Apr 1223 1228
6. G. Singer Shih IeM, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) Int J Gynecol Pathol 22 1 2003 Jan 37 41
7. T. Bonome, J.Y. Lee, D.C. Park, M. Radonovich, C. Pise-Masison, and J. Brady Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 22 2005 Nov 15 10602 10612
8. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, and D.M. Gershenson Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 4 2004 Apr 496 504
9. K.K. Wong, and D. Gershenson The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary Dis Markers 23 2007 377 387
10. H.A. Risch, J.R. McLaughlin, D.E.C. Cole, B. Rosen, L. Bradley, and E. Kwan Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 2001 700 710
11. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, and H. Arango BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 12 2005 Dec 15 2807 2816
12. B.B. Roa, A.A. Boyd, K. Volcik, and C.S. Richards Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 Nat Genet 14 2 1996 Oct 185 187
13. W.H. Gotlieb, E. Friedman, R.B. Bar-Sade, A. Kruglikova, G. Hirsh-Yechezkel, and B. Modan Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors J Natl Cancer Inst 90 13 1998 Jul 1 995 1000
14. S.J. Ramus, A. Fishman, P.D.P. Pharoah, S. Yarkoni, M. Altaras, and B.A.J. Ponder Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations EJSO 27 2001 278 281
15. W.H. Gotlieb, A. Chetrit, J. Menczer, G. Hirsh-Yechezkel, F. Lubin, and E. Friedman Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer Gynecol Oncol 97 2005 780 783
16. B.A. Werness, S.J. Ramus, R.A. DiCioccio, A.S. Whittemore, K. Garlinghouse-Jones, and I. Oakley-Girvan Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry Intl J Gyn Pathol 23 2003 29 34
17. B.A. Werness, S.J. Ramus, A.S. Whittemore, K. Garlinghouse-Jones, I. Oakley-Girvan, and R.A. Dicioccio Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations Hum Pathol 31 2000 1420 1424
18. J. Boyd, Y. Sonoda, M.G. Federici, F. Bogomolniy, E. Rhei, and D.L. Maresco Clinicopathologic features of BRCA-linked and sporadic ovarian cancer JAMA 283 2000 2260 2265
19. M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, and M. Hatae Japanese Familial Ovarian Cancer Study Group. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population Clin Cancer Res 7 2001 3144 3150
20. Myriad Genetic Laboratories. Mutation prevalence tables. Online. 2006 [cited 2009 May]; [1 page]. Available from URL: http://www.myriadtests.com/ provider/brca-mutation-prevalence.htm.
21. G. Parmigiani, S. Chen, E.S. Iversen, T.M. Friebel, D.M. Finkelstein, and H. Anton-Culver Validity of models for predicting BRCA1 and BRCA2 mutations Ann Intern Med 147 2007 441 450